Li Xiang, Jin Wenke, Wu Lifeng, Wang Huan, Xie Xin, Huang Wei, Liu B O
State Key Laboratory of Southwestern Chinese Medicine Resources, School of Pharmacy and College of Medical Technology, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
Department of Biotherapy, Cancer Center and State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, 610041, China.
Oncol Res. 2024 Dec 20;33(1):67-81. doi: 10.32604/or.2024.055921. eCollection 2025.
Triple-negative breast cancer (TNBC), characterized by its lack of traditional hormone receptors and HER2, presents a significant challenge in oncology due to its poor response to conventional therapies. Autophagy is an important process for maintaining cellular homeostasis, and there are currently autophagy biomarkers that play an effective role in the clinical treatment of tumors. In contrast to targeting protein activity, intervention with protein-protein interaction (PPI) can avoid unrelated crosstalk and regulate the autophagy process with minimal interference pathways.
Here, we employed Naive Bayes, Decision Tree, and k-Nearest Neighbors to elucidate the complex PPI network associated with autophagy in TNBC, aiming to uncover novel therapeutic targets. Meanwhile, the candidate proteins interacting with Beclin 2 were initially screened in MDA-MB-231 cells using Beclin 2 as bait protein by immunoprecipitation-mass spectrometry assay, and the interaction relationship was verified by molecular docking and CO-IP experiments after intersection. Colony formation, cellular immunofluorescence, cell scratch and 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) tests were used to predict the clinical therapeutic effects of manipulating candidate PPI.
By developing three PPI classification models and analyzing over 13,000 datasets, we identified 3733 previously unknown autophagy-related PPIs. Our network analysis revealed the central role of Beclin 2 in autophagy regulation, uncovering its interactions with 39 newly identified proteins. Notably, the CO-IP studies identified the substantial interaction between Beclin 2 and Ubiquilin 1, which was anticipated by our model and discovered in immunoprecipitation-mass spectrometry assay results. Subsequently, investigations showed that overexpressing Beclin 2 increased Ubiquilin 1, promoted autophagy-dependent cell death, and inhibited proliferation and metastasis in MDA-MB-231 cells.
This study not only enhances our understanding of autophagy regulation in TNBC but also identifies the Beclin 2-Ubiquilin 1 axis as a promising target for precision therapy. These findings open new avenues for drug discovery and offer inspiration for more effective treatments for this aggressive cancer subtype.
三阴性乳腺癌(TNBC)因缺乏传统激素受体和HER2而具有独特特征,由于其对传统疗法反应不佳,在肿瘤学领域构成重大挑战。自噬是维持细胞内稳态的重要过程,目前存在一些自噬生物标志物,它们在肿瘤临床治疗中发挥着有效作用。与靶向蛋白质活性不同,干预蛋白质 - 蛋白质相互作用(PPI)可以避免无关的串扰,并以最少的干扰途径调节自噬过程。
在此,我们采用朴素贝叶斯、决策树和k近邻算法来阐明与TNBC中自噬相关的复杂PPI网络,旨在发现新的治疗靶点。同时,以Beclin 2作为诱饵蛋白,通过免疫沉淀 - 质谱分析在MDA - MB - 231细胞中初步筛选与Beclin 2相互作用的候选蛋白,交集后通过分子对接和CO - IP实验验证相互作用关系。采用集落形成、细胞免疫荧光、细胞划痕和3 -(4,5 - 二甲基噻唑 - 2 - 基)- 2,5 - 二苯基四氮唑溴盐(MTT)试验来预测操纵候选PPI的临床治疗效果。
通过开发三种PPI分类模型并分析超过13000个数据集,我们鉴定出3733个先前未知的自噬相关PPI。我们的网络分析揭示了Beclin 2在自噬调节中的核心作用,发现它与39种新鉴定的蛋白质相互作用。值得注意的是,CO - IP研究确定了Beclin 2与泛素连接蛋白1之间存在显著相互作用,这在我们的模型中有所预测,并在免疫沉淀 - 质谱分析结果中被发现。随后的研究表明,过表达Beclin 2会增加泛素连接蛋白1,促进自噬依赖性细胞死亡,并抑制MDA - MB - 231细胞的增殖和转移。
本研究不仅加深了我们对TNBC中自噬调节的理解,还确定了Beclin 2 - 泛素连接蛋白1轴作为精准治疗的一个有前景的靶点。这些发现为药物研发开辟了新途径,并为治疗这种侵袭性癌症亚型提供了更有效治疗方法的灵感。